COSMOS Pharmaceutical Corporation (JP:3349)
:3349
Want to see JP:3349 full AI Analyst Report?
3349 Stock Chart & Stats
¥6699.00
¥109.00(1.60%)
At close: 4:00 PM EST
¥6699.00
¥109.00(1.60%)
Day’s Range― - ―
52-Week Range¥6,020.00 - ¥10,045.00
Previous CloseN/A
Volume659.40K
Average Volume (3M)399.89K
Market Cap
¥499.01B
Enterprise Value¥511.67B
Total Cash (Recent Filing)¥57.04B
Total Debt (Recent Filing)¥49.96B
Price to Earnings (P/E)17.0
Beta-0.22
Next Earnings
Jul 10, 2026EPS Estimate
117.37Next Dividend Ex-DateN/A
Dividend Yield0.93%
Share Statistics
EPS (TTM)390.85
Shares Outstanding80,001,600
10 Day Avg. Volume586,980
30 Day Avg. Volume399,893
Financial Highlights & Ratios
PEG Ratio0.85
Price to Book (P/B)2.72
Price to Sales (P/S)0.69
P/FCF Ratio-814.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)401.19
Revenue Forecast (FY)¥1.09T
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthCOSMOS shows multi-year revenue expansion (mid-single-digit growth) driven by its large drugstore network and diversified product mix. Durable retail demand for pharmaceuticals and daily consumables supports steady top-line growth and reduces earnings volatility over a 2-6 month horizon.
Stable And Healthy MarginsStable gross and net margins indicate effective merchandising, category mix and cost control across stores. Healthy EBIT/EBITDA margins provide ongoing capacity to invest in operations and defend profitability against competitive pricing, supporting medium-term margin sustainability.
Prudent Balance Sheet And Strong ROEA low leverage profile and strong equity ratio give COSMOS financial flexibility to fund store expansion, inventory and capex without overreliance on external financing. Robust ROE reflects efficient capital use and supports longer-term capacity to generate shareholder returns.
Bears Say
Negative Free Cash Flow TrendDespite healthy operating cash, persistent negative free cash flow means reported earnings are not fully converting to distributable cash. Over several quarters this can constrain reinvestment, restrict dividend or buyback flexibility, and increase reliance on financing for growth.
Rising Total Debt Needs MonitoringAlthough current leverage is low, the trend of rising debt could erode financial flexibility if continued. Higher debt raises interest and refinancing risk, limiting ability to pursue opportunistic M&A or aggressive store rollout without impacting credit metrics over the medium term.
Slight Decline In EBIT MarginA recent dip in EBIT margin signals emerging cost pressure or intensifying competition in certain categories. If structural (e.g., labor or logistics inflation, or pricing pressure), it could compress profitability unless offset by pricing, assortment optimization, or further efficiency gains.
COSMOS Pharmaceutical Corporation News
3349 FAQ
What was COSMOS Pharmaceutical Corporation’s price range in the past 12 months?
COSMOS Pharmaceutical Corporation lowest stock price was ¥6020.00 and its highest was ¥10045.00 in the past 12 months.
What is COSMOS Pharmaceutical Corporation’s market cap?
COSMOS Pharmaceutical Corporation’s market cap is ¥499.01B.
When is COSMOS Pharmaceutical Corporation’s upcoming earnings report date?
COSMOS Pharmaceutical Corporation’s upcoming earnings report date is Jul 10, 2026 which is in 51 days.
How were COSMOS Pharmaceutical Corporation’s earnings last quarter?
COSMOS Pharmaceutical Corporation released its earnings results on Apr 13, 2026. The company reported ¥102.19 earnings per share for the quarter, beating the consensus estimate of ¥100.689 by ¥1.501.
Is COSMOS Pharmaceutical Corporation overvalued?
According to Wall Street analysts COSMOS Pharmaceutical Corporation’s price is currently Overvalued.
Does COSMOS Pharmaceutical Corporation pay dividends?
COSMOS Pharmaceutical Corporation pays a Semiannually dividend of ¥37.5 which represents an annual dividend yield of 0.93%. See more information on COSMOS Pharmaceutical Corporation dividends here
What is COSMOS Pharmaceutical Corporation’s EPS estimate?
COSMOS Pharmaceutical Corporation’s EPS estimate is 117.37.
How many shares outstanding does COSMOS Pharmaceutical Corporation have?
COSMOS Pharmaceutical Corporation has 80,001,600 shares outstanding.
What happened to COSMOS Pharmaceutical Corporation’s price movement after its last earnings report?
COSMOS Pharmaceutical Corporation reported an EPS of ¥102.19 in its last earnings report, beating expectations of ¥100.689. Following the earnings report the stock price went down -1.121%.
Which hedge fund is a major shareholder of COSMOS Pharmaceutical Corporation?
Currently, no hedge funds are holding shares in JP:3349
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
COSMOS Pharmaceutical Corporation
COSMOS Pharmaceutical Corporation operates a chain of drug stores in Japan. It also operates 1,130 stores in the Kanto, Chubu, Kansai, Chugoku, Shikoku, and Kyushu regions. The company was founded in 1983 and is headquartered in Fukuoka, Japan.
Technical Analysis
Sundrug Co
―
Sugi Holdings Co
―
TSURUHA Holdings
―
Create SD Holdings Co., Ltd.
―
KUSURI NO AOKI HOLDINGS CO.,LTD.
―
Options Prices
Currently, No data available
---